OncoMatch/Clinical Trials/NCT07389616
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Is NCT07389616 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Cidabenamine, Azacitidine for peripheral t cell lymphoma.
Treatment: Cidabenamine, Azacitidine — This study is a single-center, single-arm, prospective, phase II clinical trial designed to evaluate the efficacy and safety of Cidabenamine combined with Azacitidine as maintenance therapy following allogeneic peripheral blood hematopoietic stem cell transplantation in patients with high-risk peripheral T-cell lymphoma.During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. The study plans to enroll 40 patients in each group. Enrolled patients will undergo demographic and medical history data collection, along with assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, lymphoid gene rearrangement, and bone marrow pathology.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: allogeneic peripheral blood hematopoietic stem cell transplantation — for PTCL
Underwent allogeneic peripheral blood hematopoietic stem cell transplantation for PTCL, with no restriction on donor type
Lab requirements
Blood counts
ANC ≥ 1.0 × 10⁹/L; Platelet count (PLT) ≥ 50 × 10⁹/L
Hematological function meeting the following requirements: Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L; Platelet count (PLT) ≥ 50 × 10⁹/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify